Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

Summary

Study purpose: To evaluate if previously high-frequent (3-5 weekly) aflibercept treated neovascular age-related macular degeneration (nAMD) can be extended in their treatment interval when switched to faricimab. Primary objective: To assess the efficacy of faricimab compared to aflibercept in terms of durability at 32 weeks by extending treatment interval in previous high-frequent aflibercept treated nAMD.

Timeline

Start

2023-07-04

Primary completion

2024-09-25

Completion

2025-02-26

Drugs

Indications